
Opinion|Videos|May 19, 2025
Strengths and Weaknesses of Imaging Modalities in ccRCC
Explore the strengths and weaknesses of imaging modalities like CT, MRI, and ultrasound in diagnosing ccRCC and enhancing patient care.
Advertisement
Episodes in this series

Strengths and Limitations of Different Imaging Modalities
Main Discussion Topics:
- CT scans remain the most common initial imaging modality for renal mass detection.
- MRI offers additional sequencing capabilities for better tumor characterization.
- Ultrasound primarily helps determine whether masses are solid or cystic.
- Nuclear imaging (prostate-specific membrane antigen [PSMA] scans) shows potential but has demonstrated limited accuracy.
Key Points for Physicians:
- CT is widely available and familiar to most clinicians.
- MRI provides superior soft tissue characterization and additional sequences.
- Ultrasound is useful for determining whether a mass is solid vs cystic.
- Nuclear medicine studies such as PSMA scans have not demonstrated sufficient accuracy.
Notable Insights:
Each imaging modality has specific advantages, but many patients arrive with inadequate initial imaging, requiring additional studies for proper characterization.
Clinical Significance:
Understanding the strengths and limitations of each imaging modality allows clinicians to select appropriate studies for comprehensive renal mass evaluation.
Advertisement
Related to this article

Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.

Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.

Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.

Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.

Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.

The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
Advertisement
Advertisement
Trending on Urology Times
1
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
2
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
3
Tamim Niazi, MDCM, reviews darolutamide data from DASL-HiCaP
4
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
5

